October marks Breast Cancer Awareness Month. Our CEO, Matt Coffey, Ph.D., shares his thoughts on why we need to raise awareness of one of the most common cancers, which affects approximately 1 in 8 women in the United States alone.
Welcome to Oncolytics Insights. Here we will provide commentary on recent news, presentations and happenings related to Oncolytics and our development programs.
Through IV deliver, pelareorep can train the immune system to engage, target and kill tumor cells . . .
Although immuno-oncology has transformed how we treat many cancers today, there are still huge roadblocks the biopharma industry must overcome before I-O therapies can reach their full potential.
Educating the Immune System to Target Disease and Send Natural Killer Cells
Matt Coffey recently spoke with Bud Wayne of CEOCFO Magazine to recount our founding story . . .
The phase 2 BRACELET-1 study will evaluate Oncolytics' pelareorep in combination with anti-PD-L1 BAVENCIO®. Despite the surge of novel immuno-oncology drugs, many patients still face resistance.
In follow up to our recent ‘Insight’ on the power of biomarkers, this backgrounder highlights our biomarker in the context of how pelareorep works, what it does and what we are doing with it, using graphics to demonstrate the measurement of…
Using T-Cell Clonality to Predict and Broaden Which Patients Will Respond to Checkpoint Blockade Matt Coffey recently spoke about “the power of the biomarker” at the Annual General Meeting on May 2, 2019. Listen to the full webcast, and read an…
What do we mean by an “on-treatment” predictive biomarker for immunotherapy? Dirk Arnold MD, Ph.D., Executive Board Member of the European Society of Medical Oncology (ESMO) & Chief of Oncology at Asklepios Klinik Altona, recently…
AACR 2019 Snapshot: A First Look at Predictive Biomarker Data from a Combination Study of Pelareorep + Keytruda® in Pancreatic Cancer
AACR 2019 was an important conference for us. We’ve been investigating the potential utility of a biomarker to help predict a patients response to receiving pelareorep combined with other immunotherapies, such as checkpoint inhibitors. This study is a first look at the utility of T cell clonality as a predictor of response to therapy, and we’re very excited about it.
During our presentation at the BIO CEO Investor conference, CEO Matt Coffey provided the backstory on the genesis of our AWARE-1 window of opportunity study and the intention to find a biomarker that would support a phase 3 registration study in metastatic breast cancer.